L Portalone

947 total citations
26 papers, 668 citations indexed

About

L Portalone is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Epidemiology. According to data from OpenAlex, L Portalone has authored 26 papers receiving a total of 668 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Epidemiology. Recurrent topics in L Portalone's work include Lung Cancer Research Studies (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer therapeutics and mechanisms (6 papers). L Portalone is often cited by papers focused on Lung Cancer Research Studies (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Cancer therapeutics and mechanisms (6 papers). L Portalone collaborates with scholars based in Italy, United States and Malaysia. L Portalone's co-authors include Filippo de Marinis, Monica Rinaldi, Alessandra Ravaioli, Maurizio Tonato, M. Marangolo, Cesare Gridelli, M. Sassi, Giorgio V. Scagliotti, Roberto Bianco and Sandro Barni and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

L Portalone

26 papers receiving 632 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
L Portalone Italy 11 427 418 156 84 73 26 668
Ramón Palmero Spain 14 328 0.8× 384 0.9× 159 1.0× 79 0.9× 62 0.8× 50 646
Emiddio Barletta Italy 12 336 0.8× 395 0.9× 92 0.6× 82 1.0× 66 0.9× 28 584
Alessandro Bertolini Italy 11 532 1.2× 515 1.2× 124 0.8× 65 0.8× 103 1.4× 22 760
Caio Max S. Rocha Lima United States 14 253 0.6× 537 1.3× 204 1.3× 114 1.4× 102 1.4× 39 735
Giuseppe De Cataldis Italy 8 518 1.2× 529 1.3× 77 0.5× 60 0.7× 49 0.7× 14 708
Eugene Paschold United States 8 347 0.8× 428 1.0× 154 1.0× 83 1.0× 33 0.5× 12 592
Lambros Vamvakas Greece 17 370 0.9× 597 1.4× 114 0.7× 164 2.0× 71 1.0× 44 759
Ryo Toyozawa Japan 17 629 1.5× 618 1.5× 182 1.2× 105 1.3× 66 0.9× 89 932
Giuseppe Colantuoni Italy 13 182 0.4× 317 0.8× 185 1.2× 86 1.0× 42 0.6× 28 509
Sasja F. Mulder Netherlands 12 340 0.8× 253 0.6× 265 1.7× 130 1.5× 43 0.6× 38 669

Countries citing papers authored by L Portalone

Since Specialization
Citations

This map shows the geographic impact of L Portalone's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L Portalone with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L Portalone more than expected).

Fields of papers citing papers by L Portalone

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L Portalone. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L Portalone. The network helps show where L Portalone may publish in the future.

Co-authorship network of co-authors of L Portalone

This figure shows the co-authorship network connecting the top 25 collaborators of L Portalone. A scholar is included among the top collaborators of L Portalone based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L Portalone. L Portalone is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Arcangeli, Stefano, Linda Agolli, L Portalone, et al.. (2015). Patterns of CT lung injury and toxicity after stereotactic radiotherapy delivered with helical tomotherapy in early stage medically inoperable NSCLC. British Journal of Radiology. 88(1048). 20140728–20140728. 12 indexed citations
2.
Rosti, Giovanni, et al.. (2006). Small cell lung cancer. Annals of Oncology. 17. ii5–ii10. 57 indexed citations
3.
Gridelli, Cesare, C. Manegold, P Mali, et al.. (2004). Oral vinorelbine given as monotherapy to advanced, elderly NSCLC patients: a multicentre phase II trial. European Journal of Cancer. 40(16). 2424–2431. 36 indexed citations
4.
Mangone, Massimiliano, et al.. (2004). PCNI4 ALCEA (ADVANCED LUNG CANCER ECONOMIC ASSESSMENT). Value in Health. 7(6). 673–673. 1 indexed citations
5.
Perrone, Fabiana, et al.. (2004). Cost of non-small cell lung cancer in Italy. Results of the longitudinal study ALCEA (Advanced Lung Cancer Economic Assessment). Journal of Clinical Oncology. 22(14_suppl). 8265–8265. 3 indexed citations
6.
Portalone, L. (2003). Low dose spiral computed tomography.. PubMed. 57(5-6). 291–2. 1 indexed citations
7.
Zaniboni, Alberto, Andrea Ardizzoni, Filippo de Marinis, et al.. (2003). Phase II Study of Taxol Combined With Ifosfamide and Carboplatin in the Treatment of Stage IIIb–IV Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 26(1). 84–88. 6 indexed citations
8.
Marinis, Filippo de, Maria Rita Migliorino, Luca Paoluzzi, et al.. (2003). Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer. Lung Cancer. 39(3). 331–338. 10 indexed citations
9.
Fabi, Alessandra, Salvatore Di Lauro, L Portalone, et al.. (2003). Is delayed chemotherapy-induced emesis well managed in oncological clinical practice?. Supportive Care in Cancer. 11(3). 156–161. 45 indexed citations
10.
Marinis, Filippo de, Fabrizio Nelli, Maria Rita Migliorino, et al.. (2003). Gemcitabine, paclitaxel, and cisplatin as induction chemotherapy for patients with biopsy‐proven Stage IIIA(N2) nonsmall cell lung carcinoma. Cancer. 98(8). 1707–1715. 33 indexed citations
11.
12.
Portalone, L, Andrea Altieri, Santi Barbera, et al.. (2001). Preventive epoetin a (EPO) use in the treatment of advanced nsclc: an AIPO oncology study group multicenter trial. European Journal of Cancer. 37. S56–S56. 1 indexed citations
13.
Marinis, Filippo de, Enrico Cortesi, Luca Paoluzzi, et al.. (2000). Cisplatin (P), etoposide (E) and gemcitabine (G), in untreated patients with small cell lung cancer (SCLC): Preliminary results of a multi-institutional phase II trial. Lung Cancer. 29(1). 67–67. 3 indexed citations
14.
Marinis, Filippo de, Monica Rinaldi, Andrea Ardizzoni, et al.. (1999). The Role of Vindesine and Lonidamine in the Treatment of Elderly Patients with Advanced Non-small Cell Lung Cancer: A Phase III Randomized Fonicap Trial. Tumori Journal. 85(3). 177–182. 29 indexed citations
15.
Crinò, Lucio, Giorgio V. Scagliotti, Serafino Ricci, et al.. (1999). Gemcitabine and Cisplatin Versus Mitomycin, Ifosfamide, and Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Randomized Phase III Study of the Italian Lung Cancer Project. Journal of Clinical Oncology. 17(11). 3522–3530. 302 indexed citations
16.
Paone, G, Stefano Greco, L Portalone, et al.. (1997). Evaluation of response to chemotherapy in patients affected with non-small cell lung cancer by means of three tumour markers elaborated by discriminant analysis. Respiratory Medicine. 91(6). 361–367. 7 indexed citations
17.
18.
Salvati, F, et al.. (1996). Combined treatment with thymosin-alpha1 and low-dose interferon-alpha after ifosfamide in non-small cell lung cancer: a phase-II controlled trial.. PubMed. 16(2). 1001–4. 38 indexed citations
19.
Ardizzoni, Andrea, Editta Baldini, L Portalone, et al.. (1995). Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. British Journal of Cancer. 71(1). 115–119. 18 indexed citations
20.
Rosso, R., Andrea Ardizzoni, A. Rubagotti, et al.. (1989). Etoposide v etoposide and cisplatin in the treatment of advanced non-small cell lung cancer: A FONICAP randomized study. Lung Cancer. 5(2-3). 113–113. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ramón Palmero Breakdown of academic impact, for papers by Emiddio Barletta Breakdown of academic impact, for papers by Alessandro Bertolini Breakdown of academic impact, for papers by Caio Max S. Rocha Lima Breakdown of academic impact, for papers by Giuseppe De Cataldis Breakdown of academic impact, for papers by Eugene Paschold Breakdown of academic impact, for papers by Lambros Vamvakas Breakdown of academic impact, for papers by Ryo Toyozawa Breakdown of academic impact, for papers by Giuseppe Colantuoni Breakdown of academic impact, for papers by Sasja F. Mulder
Rankless by CCL
2026